Abstracts tagged "Rheumatoid Factor"

Abstract Number: 423 • 2013 ACR/ARHP Annual Meeting
Serological Biomarkers For The Development Of Rheumatoid Arthritis Related Interstitial Lung Disease
Elena Nikiphorou¹, Esther Chan², Vadivelu Saravanan², Julie Dawson³, Navtej Sathi⁴, Felix Woodhead⁵, Mohamed Nisar⁶, Subhashini Arthanari⁶, Yasmeen Ahmad⁷, Adam Young⁸ and Clive Kelly², ¹Research Department of Epidemiology & Public Health, UCL and Rheumatology Department, St Albans City Hospital, ERAS, St Albans City Hospital & University College London (UCL), London, United Kingdom, ²Rheumatology, Queen Elizabeth Hospital, Gateshead, United Kingdom, ³Rheumatology, St Helens Hospital, St Helens, United Kingdom, ⁴Rheumatology, Wrightington Hospital, Wigan, United Kingdom, ⁵Respiratory, University Hospitals Coventry and Warwickshire, Coventry, United Kingdom, ⁶Rheumatology, Burton Hospital, Burton-on-Trent, United Kingdom, ⁷Department of Rheumatology, Peter Maddison Research Centre, Bangor, United Kingdom, ⁸Rheumatology, ERAS, St Albans City Hospital, St Albans, United Kingdom
Background/Purpose: Interstitial Lung Disease (ILD) is the commonest manifestation of lung disease in Rheumatoid Arthritis (RA) and the only complication reported to be increasing in…
Abstract Number: 183 • 2013 ACR/ARHP Annual Meeting
The Performance Of a Point Of Care Test For Detection Of Anti-Mutated Citrullinated Vimentin and Rheumatoid Factor In Early Rheumatoid Arthritis
Preeda Rojanasantikul¹, Prapa Pattrapornpisut², Kulvara Anuruckparadorn³ and Wanruchada Katchamart¹, ¹Division of Rheumatology, Department of Internal Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand, ²Department of Internal Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ³Department of Transfusion Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
Background/Purpose: Besides rheumatoid factor (RF), anti-cyclic citrullinated peptide antibody (ACPA), a newer serologic marker, was added to the new American College of Rheumatology (ACR)/European League…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].